The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform

Charles C. Guo - One of the best experts on this subject based on the ideXlab platform.

  • CASE REPORT: Plasmacytoid urothelial Carcinoma of the urinary bladder: Two case reports
    Basic and Applied Pathology, 2010
    Co-Authors: Marlo M. Nicolas, Alma J. Sanchez-salazar, Charles C. Guo
    Abstract:

    We report two cases of plasmacytoid urothelial Carcinoma of the urinary bladder. The tumor in the first case presented as an irregular and erythematous urinary bladder lesion with pararectal or rectal tumor extension. Perineal, scrotal and intrabdominal metastases developed within 4 months despite neoadjuvant chemotherapy. A muscle-invasive urinary bladder tumor was seen in the second case with perivesical and perivesicular extension and regional lymph metastases at cystoprostatectomy. The tumor cells in both cases were nested or dyscohesive, and resembled plasma cells; focal signet ring cells were also seen in the second case. The advanced stage of both cases is consistent with the reported aggressive biologic course of most of these tumors. Awareness of this rare variant when dealing with Urogenital Tract Carcinoma is important since the morphology may suggest another diagnosis. Because of peculiar expression of CD138, a plasma cell-associated marker, these tumors may be mistaken for a plasma cell-derived neoplasm.

Marlo M. Nicolas - One of the best experts on this subject based on the ideXlab platform.

  • CASE REPORT: Plasmacytoid urothelial Carcinoma of the urinary bladder: Two case reports
    Basic and Applied Pathology, 2010
    Co-Authors: Marlo M. Nicolas, Alma J. Sanchez-salazar, Charles C. Guo
    Abstract:

    We report two cases of plasmacytoid urothelial Carcinoma of the urinary bladder. The tumor in the first case presented as an irregular and erythematous urinary bladder lesion with pararectal or rectal tumor extension. Perineal, scrotal and intrabdominal metastases developed within 4 months despite neoadjuvant chemotherapy. A muscle-invasive urinary bladder tumor was seen in the second case with perivesical and perivesicular extension and regional lymph metastases at cystoprostatectomy. The tumor cells in both cases were nested or dyscohesive, and resembled plasma cells; focal signet ring cells were also seen in the second case. The advanced stage of both cases is consistent with the reported aggressive biologic course of most of these tumors. Awareness of this rare variant when dealing with Urogenital Tract Carcinoma is important since the morphology may suggest another diagnosis. Because of peculiar expression of CD138, a plasma cell-associated marker, these tumors may be mistaken for a plasma cell-derived neoplasm.

Alma J. Sanchez-salazar - One of the best experts on this subject based on the ideXlab platform.

  • CASE REPORT: Plasmacytoid urothelial Carcinoma of the urinary bladder: Two case reports
    Basic and Applied Pathology, 2010
    Co-Authors: Marlo M. Nicolas, Alma J. Sanchez-salazar, Charles C. Guo
    Abstract:

    We report two cases of plasmacytoid urothelial Carcinoma of the urinary bladder. The tumor in the first case presented as an irregular and erythematous urinary bladder lesion with pararectal or rectal tumor extension. Perineal, scrotal and intrabdominal metastases developed within 4 months despite neoadjuvant chemotherapy. A muscle-invasive urinary bladder tumor was seen in the second case with perivesical and perivesicular extension and regional lymph metastases at cystoprostatectomy. The tumor cells in both cases were nested or dyscohesive, and resembled plasma cells; focal signet ring cells were also seen in the second case. The advanced stage of both cases is consistent with the reported aggressive biologic course of most of these tumors. Awareness of this rare variant when dealing with Urogenital Tract Carcinoma is important since the morphology may suggest another diagnosis. Because of peculiar expression of CD138, a plasma cell-associated marker, these tumors may be mistaken for a plasma cell-derived neoplasm.

Jörg M. Steiner - One of the best experts on this subject based on the ideXlab platform.

  • Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or Urogenital Tract Carcinoma
    BMC Veterinary Research, 2017
    Co-Authors: Romy M. Heilmann, David J. Lanerie, Jan S. Suchodolski, Elizabeth A. Mcniel, Niels Grützner, Jörg M. Steiner
    Abstract:

    Background Onset of canine transitional cell Carcinoma (TCC) and prostatic Carcinoma (PCA) is usually insidious with dogs presenting at an advanced stage of the disease. A biomarker that can facilitate early detection of TCC/PCA and improve patient survival would be useful. S100A8/A9 (calgranulin A/B or calprotectin) and S100A12 (calgranulin C) are expressed by cells of the innate immune system and are associated with several inflammatory disorders. S100A8/A9 is also expressed by epithelial cells after malignant transformation and is involved in the regulation of cell proliferation and metastasis. S100A8/A9 is up-regulated in human PCA and TCC, whereas the results for S100A12 have been ambiguous. Also, the urine S100A8/A9-to-S100A12 ratio (uCalR) may have potential as a marker for canine TCC/PCA. Aim of the study was to evaluate the diagnostic accuracy of the urinary S100/calgranulins to detect TCC/PCA in dogs by using data and urine samples from 164 dogs with TCC/PCA, non-neoplastic urinary Tract disease, other neoplasms, or urinary Tract infections, and 75 healthy controls (nested case-control study). Urine S100A8/A9 and S100A12 (measured by species-specific radioimmunoassays and normalized against urine specific gravity [S100A8/A9_USG; S100A12_USG], urine creatinine concentration, and urine protein concentration and the uCalR were compared among the groups of dogs. Results S100A8/A9_USG had the highest sensitivity (96%) and specificity (66%) to detect TCC/PCA, with specificity reaching 75% after excluding dogs with a urinary Tract infection. The uCalR best distinguished dogs with TCC/PCA from dogs with a urinary Tract infection (sensitivity: 91%, specificity: 60%). Using a S100A8/A9_USG ≥ 109.9 to screen dogs ≥6 years of age for TCC/PCA yielded a negative predictive value of 100%. Conclusions S100A8/A9_USG and uCalR may have utility for diagnosing TCC/PCA in dogs, and S100A8/A9_USG may be a good screening test for canine TCC/PCA.

  • Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or Urogenital Tract Carcinoma.
    BMC veterinary research, 2017
    Co-Authors: Romy M. Heilmann, David J. Lanerie, Jan S. Suchodolski, Elizabeth A. Mcniel, Niels Grützner, Jörg M. Steiner
    Abstract:

    Onset of canine transitional cell Carcinoma (TCC) and prostatic Carcinoma (PCA) is usually insidious with dogs presenting at an advanced stage of the disease. A biomarker that can facilitate early detection of TCC/PCA and improve patient survival would be useful. S100A8/A9 (calgranulin A/B or calprotectin) and S100A12 (calgranulin C) are expressed by cells of the innate immune system and are associated with several inflammatory disorders. S100A8/A9 is also expressed by epithelial cells after malignant transformation and is involved in the regulation of cell proliferation and metastasis. S100A8/A9 is up-regulated in human PCA and TCC, whereas the results for S100A12 have been ambiguous. Also, the urine S100A8/A9-to-S100A12 ratio (uCalR) may have potential as a marker for canine TCC/PCA. Aim of the study was to evaluate the diagnostic accuracy of the urinary S100/calgranulins to detect TCC/PCA in dogs by using data and urine samples from 164 dogs with TCC/PCA, non-neoplastic urinary Tract disease, other neoplasms, or urinary Tract infections, and 75 healthy controls (nested case-control study). Urine S100A8/A9 and S100A12 (measured by species-specific radioimmunoassays and normalized against urine specific gravity [S100A8/A9USG; S100A12USG], urine creatinine concentration, and urine protein concentration and the uCalR were compared among the groups of dogs. S100A8/A9USG had the highest sensitivity (96%) and specificity (66%) to detect TCC/PCA, with specificity reaching 75% after excluding dogs with a urinary Tract infection. The uCalR best distinguished dogs with TCC/PCA from dogs with a urinary Tract infection (sensitivity: 91%, specificity: 60%). Using a S100A8/A9USG ≥ 109.9 to screen dogs ≥6 years of age for TCC/PCA yielded a negative predictive value of 100%. S100A8/A9USG and uCalR may have utility for diagnosing TCC/PCA in dogs, and S100A8/A9USG may be a good screening test for canine TCC/PCA.

Romy M. Heilmann - One of the best experts on this subject based on the ideXlab platform.

  • Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or Urogenital Tract Carcinoma
    BMC Veterinary Research, 2017
    Co-Authors: Romy M. Heilmann, David J. Lanerie, Jan S. Suchodolski, Elizabeth A. Mcniel, Niels Grützner, Jörg M. Steiner
    Abstract:

    Background Onset of canine transitional cell Carcinoma (TCC) and prostatic Carcinoma (PCA) is usually insidious with dogs presenting at an advanced stage of the disease. A biomarker that can facilitate early detection of TCC/PCA and improve patient survival would be useful. S100A8/A9 (calgranulin A/B or calprotectin) and S100A12 (calgranulin C) are expressed by cells of the innate immune system and are associated with several inflammatory disorders. S100A8/A9 is also expressed by epithelial cells after malignant transformation and is involved in the regulation of cell proliferation and metastasis. S100A8/A9 is up-regulated in human PCA and TCC, whereas the results for S100A12 have been ambiguous. Also, the urine S100A8/A9-to-S100A12 ratio (uCalR) may have potential as a marker for canine TCC/PCA. Aim of the study was to evaluate the diagnostic accuracy of the urinary S100/calgranulins to detect TCC/PCA in dogs by using data and urine samples from 164 dogs with TCC/PCA, non-neoplastic urinary Tract disease, other neoplasms, or urinary Tract infections, and 75 healthy controls (nested case-control study). Urine S100A8/A9 and S100A12 (measured by species-specific radioimmunoassays and normalized against urine specific gravity [S100A8/A9_USG; S100A12_USG], urine creatinine concentration, and urine protein concentration and the uCalR were compared among the groups of dogs. Results S100A8/A9_USG had the highest sensitivity (96%) and specificity (66%) to detect TCC/PCA, with specificity reaching 75% after excluding dogs with a urinary Tract infection. The uCalR best distinguished dogs with TCC/PCA from dogs with a urinary Tract infection (sensitivity: 91%, specificity: 60%). Using a S100A8/A9_USG ≥ 109.9 to screen dogs ≥6 years of age for TCC/PCA yielded a negative predictive value of 100%. Conclusions S100A8/A9_USG and uCalR may have utility for diagnosing TCC/PCA in dogs, and S100A8/A9_USG may be a good screening test for canine TCC/PCA.

  • Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or Urogenital Tract Carcinoma.
    BMC veterinary research, 2017
    Co-Authors: Romy M. Heilmann, David J. Lanerie, Jan S. Suchodolski, Elizabeth A. Mcniel, Niels Grützner, Jörg M. Steiner
    Abstract:

    Onset of canine transitional cell Carcinoma (TCC) and prostatic Carcinoma (PCA) is usually insidious with dogs presenting at an advanced stage of the disease. A biomarker that can facilitate early detection of TCC/PCA and improve patient survival would be useful. S100A8/A9 (calgranulin A/B or calprotectin) and S100A12 (calgranulin C) are expressed by cells of the innate immune system and are associated with several inflammatory disorders. S100A8/A9 is also expressed by epithelial cells after malignant transformation and is involved in the regulation of cell proliferation and metastasis. S100A8/A9 is up-regulated in human PCA and TCC, whereas the results for S100A12 have been ambiguous. Also, the urine S100A8/A9-to-S100A12 ratio (uCalR) may have potential as a marker for canine TCC/PCA. Aim of the study was to evaluate the diagnostic accuracy of the urinary S100/calgranulins to detect TCC/PCA in dogs by using data and urine samples from 164 dogs with TCC/PCA, non-neoplastic urinary Tract disease, other neoplasms, or urinary Tract infections, and 75 healthy controls (nested case-control study). Urine S100A8/A9 and S100A12 (measured by species-specific radioimmunoassays and normalized against urine specific gravity [S100A8/A9USG; S100A12USG], urine creatinine concentration, and urine protein concentration and the uCalR were compared among the groups of dogs. S100A8/A9USG had the highest sensitivity (96%) and specificity (66%) to detect TCC/PCA, with specificity reaching 75% after excluding dogs with a urinary Tract infection. The uCalR best distinguished dogs with TCC/PCA from dogs with a urinary Tract infection (sensitivity: 91%, specificity: 60%). Using a S100A8/A9USG ≥ 109.9 to screen dogs ≥6 years of age for TCC/PCA yielded a negative predictive value of 100%. S100A8/A9USG and uCalR may have utility for diagnosing TCC/PCA in dogs, and S100A8/A9USG may be a good screening test for canine TCC/PCA.